达雷妥尤单抗联合全反式维甲酸治疗复发难治多发性骨髓瘤的疗效与安全性
这项1/2期研究评估了达雷妥尤单抗联合全反式维甲酸(ATRA)在达雷妥尤单抗难治性多发性骨髓瘤患者中的最佳剂量、疗效和安全性。中位随访43个月,中位无进展生存期(PFS)为2.8个月,中位总生存期为19.1个月,加用ATRA未增加不良事件发生率。
要点
- ATRA推荐2期剂量为45 mg/m2,联合达雷妥尤单抗的ORR仅5%,未达到ORR≥15%的主要终点。
- 全体患者中位PFS为2.8个月,中位OS为19.1个月。
- 既往达雷妥尤单抗单药治疗获≥PR或MR/SD者PFS显著长于立即进展者(3.4和2.8 vs 1.3个月)。
核心结论
- 在达雷妥尤单抗难治性多发性骨髓瘤患者中,加用ATRA并再强化达雷妥尤单抗的活性有限,可能与CD38表达短暂上调有关。
研究设计与样本
- 1/2期研究(NCT02751255),A部分63例患者接受达雷妥尤单抗单药治疗。
主要发现
- ATRA联合达雷妥尤单抗的推荐2期剂量为45 mg/m2。
- 该剂量下ORR为5%,未达到主要终点(ORR≥15%),但66%的患者至少达到疾病稳定。
- 中位随访43个月,全体患者中位PFS为2.8个月,中位OS为19.1个月。
- 既往达雷妥尤单抗单药治疗获≥PR或MR/SD者中位PFS为3.4和2.8个月,立即进展者为1.3个月。
- 加用ATRA未增加不良事件发生率;流式细胞术显示ATRA暂时增加免疫细胞亚群CD38表达。
关键数值与推荐
- ATRA推荐2期剂量为45 mg/m2(联合达雷妥尤单抗)。
- 主要终点ORR≥15%未达到,实际ORR为5%。
- 全体患者中位PFS为2.8个月,中位OS为19.1个月。
临床怎么用
- 对于达雷妥尤单抗难治性多发性骨髓瘤,加用ATRA并再强化达雷妥尤单抗的获益有限。
- 既往达雷妥尤单抗单药治疗曾获≥PR或MR/SD的患者可能从该联合方案中获得更长PFS。
局限性
- ATRA对CD38表达的上调是暂时的,可能限制联合方案的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We have previously shown that all-trans retinoic acid (ATRA) upregulates CD38 expression and reverts daratumumab-resistance ex vivo. We therefore evaluated the optimal dose, efficacy, and safety of daratumumab combined with ATRA in patients with daratumumab-refractory MM in a phase 1/2 study (NCT02751255). In part A of the study, 63 patients were treated with daratumumab monotherapy. Fifty patients with daratumumab-refractory MM were subsequently enrolled in part B and treated with daratumumab (reintensified schedule) combined with ATRA until disease progression. The recommended phase 2 dose of ATRA in combination with daratumumab was defined as 45 mg/m2. At this dose, the overall response rate (ORR) was 5%, indicating that the primary endpoint (ORR ≥15%) was not met. However, most patients (66%) achieved at least stable disease. After a median follow-up of 43 months, the median progression-free survival (PFS) for all patients was 2.8 months. Patients who previously achieved at least a partial response or minimal response/stable disease with prior daratumumab monotherapy had a significantly longer PFS compared with patients who immediately progressed during daratumumab as single agent (median PFS 3.4 and 2.8 vs 1.3 months). The median overall survival was 19.1 months. The addition of ATRA did not increase the incidence of adverse events. Flow cytometric analysis revealed that ATRA temporarily increased CD38 expression on immune cell subsets. In conclusion, the addition of ATRA and reintensification of daratumumab had limited activity in patients with daratumumab-refractory MM, which may be explained by the transient upregulation of CD38 expression. This trial was registered at www.clinicaltrials.gov as #NCT02751255.
引用
- Frerichs KA, Minnema MC, Levin MD, et al. Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. Blood Adv. 2021. PMID: 34625791. doi:10.1182/bloodadvances.2021005220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。